Literature DB >> 24897671

Behavioural validation of a light/dark choice procedure for testing anti-anxiety agents.

R Misslin1, C Belzung1, E Vogel1.   

Abstract

In order to teat the behavioural value of a two-chambered light/dark choice procedure used for pharmacological studies, we investigated the effects of several internal and external factors on two variables: the time spent by mice in the lit box (TLB) and the number of transitions between the lit box and the dark one. The present results indicate that this procedure can be considered as an unconditioned conflict paradigm based at once on the innate tendency of mice to seek refuge in a dark box and their propensity to escape novel places into which they have been forced. It is suggested that this test is particularly well adopted to measuring the antiaversive properties of the so called "anxiolytic" drugs. © 1989 Elsevier Science Publishers B.V. (Biomedical Division). All rights reserved.

Entities:  

Keywords:  aversion; genotype; light intensity; light/dark choice procedure; mice; previous stress; social isolation; time course

Year:  2014        PMID: 24897671     DOI: 10.1016/S0376-6357(89)80010-5

Source DB:  PubMed          Journal:  Behav Processes        ISSN: 0376-6357            Impact factor:   1.777


  17 in total

1.  Prophylactic actions of the antioxidant agent AEKOL on behavioral (psychoemotional) disturbances induced by chronic stress in rats.

Authors:  M A Kulikov
Journal:  Neurosci Behav Physiol       Date:  2001 Sep-Oct

2.  Modulation of exploratory behavior in female mice by protein-borne male urinary molecules.

Authors:  Carla Mucignat-Caretta
Journal:  J Chem Ecol       Date:  2002-09       Impact factor: 2.626

3.  Comparison of the behavioural effects of an adenosine A1/A2-receptor antagonist, CGS 15943A, and an A1-selective antagonist, DPCPX.

Authors:  G Griebel; M Saffroy-Spittler; R Misslin; D Remmy; E Vogel; J J Bourguignon
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.

Authors:  Mark D Black; Rachel J Stevens; Nancy Rogacki; Robert E Featherstone; Yaw Senyah; Odessa Giardino; Beth Borowsky; Jeanne Stemmelin; Caroline Cohen; Philippe Pichat; Michal Arad; Segev Barak; Amaya De Levie; Ina Weiner; Guy Griebel; Geoffrey B Varty
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

5.  LY 171555-induced hyperdefensiveness in the mouse does not implicate benzodiazepine receptors.

Authors:  C Belzung; S Cabib; L Fabiani; P Tolentino; S Puglisi-Allegra
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

6.  Serenics fluprazine (DU 27716) and eltoprazine (DU 28853) enhance neophobic and emotional behaviour in mice.

Authors:  G Griebel; M Saffroy-Spittler; R Misslin; E Vogel; J R Martin
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.

Authors:  Guy Griebel; Jacques Simiand; Claudine Serradeil-Le Gal; Jean Wagnon; Marc Pascal; Bernard Scatton; Jean-Pierre Maffrand; Philippe Soubrie
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

8.  Stress-induced alterations in anxiety-like behavior and adaptations in plasticity in the bed nucleus of the stria terminalis.

Authors:  Kelly L Conrad; Katherine M Louderback; Caitlin P Gessner; Danny G Winder
Journal:  Physiol Behav       Date:  2011-03-08

9.  Sex-specific behavioral effects following developmental exposure to tetrabromobisphenol A (TBBPA) in Wistar rats.

Authors:  Kylie D Rock; Sagi Enicole A Gillera; Pratyush Devarasetty; Brian Horman; Gabriel Knudsen; Linda S Birnbaum; Suzanne E Fenton; Heather B Patisaul
Journal:  Neurotoxicology       Date:  2019-09-18       Impact factor: 4.294

Review 10.  50 years of hurdles and hope in anxiolytic drug discovery.

Authors:  Guy Griebel; Andrew Holmes
Journal:  Nat Rev Drug Discov       Date:  2013-09       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.